Product Information
MESALAMINE ER 0.375 GRAM CAP is a generic product labeled by Alembic Pharmaceuticals Inc., priced at $0.4780 per EA under NDC 62332072435. Its NADAC has been published 150 times since Nov 22, 2023.
FDA first approved this application on Oct 28, 2022. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
.375 g/1
Manufacturer
Alembic Pharmaceuticals Inc.NDC
62332072435
Classification
Generic
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
MESALAMINEApproval Type
Generic (ANDA)
FDA Application
ANDA216967FDA Approved
10/28/2022
TE Code
AB
On Market Since
11/3/2022
Pharmacological Classes
Price Statistics
The NADAC for MESALAMINE ER 0.375 GRAM CAP has been published 150 times since Nov 22, 2023, and over the history we have for it it has declined 41.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.4780 per EA |
|---|---|
| All-time high | $0.9198 (Feb 14, 2024) |
| All-time low | $0.4196 (Feb 18, 2026) |
| 52-week high | $0.4979 |
| 52-week low | $0.4196 |
| Median price | $0.4912 |
| Average price | $0.5373 |
| Largest weekly change | -38.7% (Jul 17, 2024) |
| Weeks tracked | 150 |
| Tracking since | Nov 22, 2023 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the MESALAMINE market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Alembic Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
MESALAMINE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Aminosalicylate class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of MESALAMINE ER 0.375 GRAM CAP?
The current National Average Drug Acquisition Cost (NADAC) for MESALAMINE ER 0.375 GRAM CAP, manufactured by Alembic Pharmaceuticals Inc., is $0.4780 per EA (NDC 62332072435), effective Sep 30, 2026.
How has the price of MESALAMINE ER 0.375 GRAM CAP changed over time?
Over the history we have for it, the NADAC for MESALAMINE ER 0.375 GRAM CAP has declined 41.6%. It has been tracked across 150 weekly CMS publications since Nov 22, 2023.
What are the highest and lowest recorded NADAC prices for MESALAMINE ER 0.375 GRAM CAP?
Since Nov 22, 2023, the NADAC for MESALAMINE ER 0.375 GRAM CAP has ranged from a low of $0.4196 (Feb 18, 2026) to a high of $0.9198 (Feb 14, 2024), with a median of $0.4912 per EA.
Are there cheaper alternatives to MESALAMINE ER 0.375 GRAM CAP?
No other NADAC-published product currently shares the active ingredient and strength of MESALAMINE ER 0.375 GRAM CAP in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures MESALAMINE ER 0.375 GRAM CAP?
MESALAMINE ER 0.375 GRAM CAP (NDC 62332072435) is labeled by Alembic Pharmaceuticals Inc., and CMS classifies it as a generic product.